Drugs / AK3280
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04926116 | Jun → Sep 2021 | — | Shanghai Ark Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03990688 | Oct 2019 → Sep 2020 | — | Shanghai Ark Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05434897 | Jul 2022 → Jul 2023 | reactive cutaneous fibrous lesion | Shanghai Ark Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT05424887 | Jul 2022 → Jul 2024 | idiopathic pulmonary fibrosis | Shanghai Ark Biopharmaceutical Co., Ltd. | Unknown | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-02-12 | Ark Biosciences Pty Ltd. | Regulatory 爱科百发抗纤维化创新药AK3280获美国FDA批准开展IPF患者II期临床试验 arkbiosciences.com ↗
公司自主研发的抗纤维化创新药AK3280新药临床试验申请（IND）已获美国食品药品监督管理局（FDA）批准，可在美国直接开展特发性肺纤维化（IPF）患者的II期临床试验。 |
| 2025-05-16 | Ark Biosciences Pty Ltd. | Results 新一代抗纤维化药物AK3280治疗特发性肺纤维化II期临床研究取得积极结果 arkbiosciences.com ↗
该研究由中日友好医院呼吸与危重症医学科代华平教授牵头，全国31家临床中心共同参与。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-02-12 | Ark Biosciences Pty Ltd. | 爱科百发抗纤维化创新药AK3280获美国FDA批准开展IPF患者II期临床试验 arkbiosciences.com ↗ |
| 2025-05-16 | Ark Biosciences Pty Ltd. | 新一代抗纤维化药物AK3280治疗特发性肺纤维化II期临床研究取得积极结果 arkbiosciences.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AK3280 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05424887 ↗ |
| Known as | AK3287 | “AK3280 cream （AK3287 ） or placebo” NCT05434897 ↗ |
| Route | Oral | “Route of Administration: Oral” NCT03990688 ↗ |